Cyted

What Cyted does

Cyted is a Cambridge, UK-headquartered medical technology company developing the EndoSign® capsule sponge cell collection device combined with proprietary methylation biomarker assays for the non-endoscopic detection of esophageal conditions, primarily Barrett's Esophagus and esophageal adenocarcinoma. The device replaces sedation-dependent endoscopy with a minimally invasive, swallowable capsule that collects pan-esophageal cells in minutes, which are then analyzed in Cyted's laboratories using molecular diagnostics (including TFF3 and methylation biomarkers) and AI-assisted digital pathology screening developed in collaboration with Microsoft Research. Cyted serves public and private healthcare systems, with deep commercial traction across the UK NHS (70+ hospitals and GP surgeries in England, Scotland, Wales, and Northern Ireland, including a national programme in NHS Scotland since 2020) and an emerging US presence built around the FDA 510(k)-cleared EndoSign®, CLIA- and CAP-accredited US laboratory operations, and the DETECT-ME clinical validation study across 18 US sites.

The business model is a fee-for-service diagnostic testing platform: Cyted provides the EndoSign® device to healthcare providers, processes samples through its own accredited laboratories (CAP-accredited US lab, UK lab operations relocated to Huntingdon in 2021), and bills through multi-year contracts negotiated with NHS trusts, SBRI-funded pilots, and commercial agreements with US hospital systems. Revenue streams are anchored by diagnostic testing services and managed laboratory services, with non-dilutive grant funding (SBRI, Innovate UK, Cancer Research UK) supporting clinical pathway development and product extensions such as Eosinophilic Esophagitis testing. Go-to-market combines enterprise field sales to NHS trusts and US hospital systems with clinical evidence generation through peer-reviewed publications (Nature Medicine, Nature Communications, Lancet Oncology), clinical symposiums, and endorsements from ACG and ESGE, supported by senior commercial hires from Guardant Health, Gilead, Agendia, and Medtronic.

Cumulative funding exceeds $73 million across equity (~$44M Series B led by EQT Life Sciences in August 2025, $16.8M Series A co-led by BGF and Morningside in May 2023) and non-dilutive grants. The company employs 51-100 staff across its UK headquarters, R&D/laboratory operations, and US subsidiary Cyted Health Inc., and is led by Co-founder & CEO Marcel Gehrung PhD alongside Co-founders Prof. Rebecca Fitzgerald OBE (Chair of the Scientific Advisory Board) and Dr. Maria O'Donovan (Lead Pathologist), with Board Chair Gail Marcus and US President Betsy Hanna anchoring US commercialization.

Name

Cyted

Legal name

Cyted Ltd.

Website

https://cyted.ai

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Cyted is a Cambridge-based medical technology company that combines the FDA-cleared EndoSign® capsule sponge device with molecular biomarker assays and AI-assisted pathology to detect Barrett's Esophagus and esophageal cancer, serving the UK NHS across 70+ hospitals and expanding into US hospital systems.

Ownership category

akta.pro rank

Product category

Esophageal Cancer Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Surgical Appliance and Supplies Manufacturing (339113)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

akta.pro secondary industries

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Esophageal cancer diagnostics
• Capsule sponge testing
• Barrett's esophagus detection
• Molecular pathology diagnostics
• Non-endoscopic cell collection

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: Cyted provides diagnostic testing services through its EndoSign® platform, combining the capsule sponge device with laboratory molecular analysis. Revenue is generated from healthcare providers (NHS, US hospitals) paying for diagnostic tests and services.
2. Laboratory Services: Cyted operates laboratories providing molecular diagnostic analysis of samples collected via EndoSign® devices, serving NHS and expanding US operations.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Cyted develops and commercializes the EndoSign® (formerly Cytosponge) capsule sponge cell collection device paired with proprietary methylation biomarker molecular assays and AI-powered digital pathology screening to detect Barrett's Esophagus and esophageal cancer non-endoscopically. The company operates CLIA-certified and CAP-accredited laboratories in the UK and US that process samples collected via the device for NHS trusts, US hospital systems, and clinical research partners.

Differentiator

Problem solved

Functional benefit

Brands

• EndoSign®: Minimally-invasive capsule sponge device for safe and accessible cell collection with full esophageal sampling, combined with advanced molecular diagnostics for detection of Barrett's Esophagus and esophageal cancer prevention.

Products and services

• EndoSign® Cell Collection Device Minimally invasive, non-endoscopic capsule sponge cell collection device (FDA 510(k)-cleared) that enables safe, accessible cell collection with full esophageal sampling for healthcare providers diagnosing esophageal disease.
• Molecular Diagnostic Test for Barrett's Esophagus Proprietary methylation-based molecular assay analyzing esophageal cells collected via EndoSign® to detect Barrett's Esophagus; shown to detect 10x more cases than standard care.
• Molecular Diagnostic Test for Esophageal Neoplasia Molecular assay for detection of esophageal neoplasia and esophageal adenocarcinoma using EndoSign® collected samples, supported by AI/ML pathology screening.
• Eosinophilic Esophagitis (EoE) Testing Platform Non-endoscopic molecular testing platform under development for diagnosing and predicting treatment response for Eosinophilic Esophagitis.
• Heartburn Health Check Programme Diagnostic programme pairing EndoSign® capsule sponge cell collection with molecular analysis to screen patients with chronic GERD/heartburn for Barrett's Esophagus and esophageal cancer in community and primary care settings.
• Cyted Laboratory Services CLIA-certified and CAP-accredited laboratory services providing molecular diagnostic analysis of EndoSign® collected samples for NHS and US healthcare providers, including AI-assisted pathology screening.

Quantifiable outcome

• 78% reduction in demand for endoscopies in secondary care
• +7 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core and major.

• Devyser Genomic LaboratoriescoreTechnology or IntegrationPartnership for laboratory analysis of samples collected via EndoSign® device. Established following FDA clearance to support US commercialization.
• Microsoft ResearchcoreTechnology or IntegrationCollaboration to develop AI models for efficient screening of cancer cells. Published in Nature Communications, with AI potentially reducing pathologist workload by up to 63%. Research enables large-scale screening of Barrett's esophagus using deep learning.
• University of CambridgecoreStrategic or Co-development PartnerCyted was founded by leading experts at the University of Cambridge. Co-founder Prof. Rebecca Fitzgerald serves as Director of the Early Cancer Institute at Cambridge and developed the Cytosponge-TFF3 test from concept through clinical trial.
• MedtronicmajorOEM/ Whitelabel/ Licensing PartnerPartnership for Cytosponge device manufacturing and distribution. Medtronic collaborated on NHS pilot projects including CYTOPRIME and digital pathology initiatives.
• NHS Cancer Programme / SBRI HealthcarecoreStrategic or Co-development PartnerNHS Cancer Programme provided £3.4m non-dilutive grant for community testing expansion. SBRI Healthcare grants have funded multiple projects including CYTOPRIME1, CYTOPRIME2, and Wales/Northern Ireland pilots.
• Cancer Research UKcoreStrategic or Co-development PartnerLong-standing partnership for research and development. CRUK-funded research led to Cytosponge development. Joint funding for Project DELTA and BEST4 screening trial (jointly funded with NIHR).
• Lancashire and South Cumbria Cancer AlliancemajorStrategic or Co-development PartnerNHS partner for CYTOPRIME project demonstrating capsule sponge testing in primary care and community settings across North West England.
• Unity InsightsmajorStrategic or Co-development PartnerHealthcare analytics partner that independently evaluated Cyted's technology. Published reports demonstrating 78% reduction in endoscopy demand and significant cost savings.
• Cardiff & Vale UHBmajorImplementation/ SI/ Consulting PartnerWales pilot partner for SBRI Centre of Excellence and Innovation funded project to improve early detection of oesophageal cancer using EndoSign®.
• Belfast Health & Social Care TrustmajorImplementation/ SI/ Consulting PartnerNorthern Ireland pilot partner for SBRI-funded diagnostic pathway demonstrating sustainable model for integrating capsule sponge diagnostics into clinical pathways.
• Western Health & Social Care TrustmajorImplementation/ SI/ Consulting PartnerNorthern Ireland partner in SBRI innovation project for oesophageal cancer early detection implementing EndoSign® testing.
• Professor Rebecca Fitzgerald OBEcoreStrategic or Co-development PartnerCo-founder and Chair of Scientific Advisory Board. Professor of Cancer Prevention and Director of the Early Cancer Institute at University of Cambridge. Leading expert in BE and EAC who pioneered minimally invasive cell sampling coupled with biomarker tests.
• Chris Freeman (Strategic Advisor)majorStrategic or Co-development PartnerFormer Chief Commercial Officer of Guardant Health and VP at Gilead Sciences. Appointed as strategic advisor to advise on growth and US commercialization.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Lucid Diagnostics: Lucid's EsoCheck (capsule sponge) and EsoGuard (methylation biomarker) test directly competes with Cyted's EndoSign-plus-methylation platform for non-endoscopic Barrett's Esophagus detection, targeting the same US gastroenterology channel.
• CDx Diagnostics: CDx offers WATS³ (wide-area transepithelial sampling) for Barrett's detection, a competing non-endoscopic or minimally invasive tissue sampling method targeting the same gastroenterologist customer base as Cyted.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Cyted_UK
• LinkedInlinkedin.com/company/cyted-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries2 records

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyted